Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Purchases $97,580.00 in Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs bought 17,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The shares were bought at an average price of $5.74 per share, with a total value of $97,580.00. Following the transaction, the chief executive officer now directly owns 559,717 shares in the company, valued at $3,212,775.58. This trade represents a 3.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Lifecore Biomedical Stock Down 1.9 %

NASDAQ LFCR opened at $5.80 on Friday. The stock’s 50 day simple moving average is $7.05 and its 200 day simple moving average is $5.82. The company has a debt-to-equity ratio of 12.90, a current ratio of 1.83 and a quick ratio of 0.80. Lifecore Biomedical, Inc. has a one year low of $3.68 and a one year high of $8.90. The firm has a market cap of $213.60 million, a PE ratio of 72.50 and a beta of 0.98.

Lifecore Biomedical (NASDAQ:LFCR) last announced its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. As a group, sell-side analysts forecast that Lifecore Biomedical, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lifecore Biomedical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DCF Advisers LLC increased its holdings in shares of Lifecore Biomedical by 2.1% in the second quarter. DCF Advisers LLC now owns 290,684 shares of the company’s stock valued at $1,491,000 after purchasing an additional 6,000 shares in the last quarter. Renaissance Technologies LLC bought a new position in Lifecore Biomedical in the 2nd quarter valued at $56,000. Creative Planning bought a new position in Lifecore Biomedical in the 3rd quarter valued at $69,000. Legion Partners Asset Management LLC boosted its position in Lifecore Biomedical by 0.6% in the 2nd quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock valued at $15,228,000 after buying an additional 18,182 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Lifecore Biomedical by 101.7% during the third quarter. Jane Street Group LLC now owns 36,246 shares of the company’s stock worth $179,000 after acquiring an additional 18,277 shares during the last quarter. Institutional investors and hedge funds own 83.36% of the company’s stock.

Analysts Set New Price Targets

LFCR has been the subject of a number of analyst reports. Stephens reissued an “equal weight” rating and set a $6.00 price objective on shares of Lifecore Biomedical in a report on Friday, January 3rd. Craig Hallum increased their target price on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 22nd.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.